Philip Hollingsworth Imus, M.D.
Dr. Philip Imus is an oncologist in the Baltimore area, caring for patients with hematologic malignancies.
Dr. Imus received his undergraduate degree (cum laude) in English from Rice University. He earned his M.D. from Columbia University College of Physicians and Surgeons. He completed his residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center and performed a fellowship in oncology at Johns Hopkins.
DeZern AE, Zahurak ML, Symons HJ, Cooke KR, Rosner GL, Gladstone DE, Huff CA, Swinnen LJ, Imus P, Borrello I, Wagner-Johnston N, Ambinder RF, Luznik L, Bolaños-Meade J, Fuchs EJ, Jones RJ, Brodsky RA. “Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide.” Blood Adv. 2020 Apr 28;4(8):1770-1779. doi: 10.1182/bloodadvances.2020001729
Imus PH, Blackford AL, Bettinotti M, Luznik L, Fuchs EJ, Huff CA, Gladstone DE, Ambinder RF, Borrello IM, Fuchs RJ, Swinnen LJ, Wagner-Johnston N, Gocke CB, Ali SA, Bolaños-Meade FJ, Jones RJ, Dezern AE. “Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation.” Biol Blood Marrow Transplant. 2019 Dec;25(12):2431-2437
Imus PH, Tsai HL, Luznik L, Fuchs EJ, Huff CA, Gladstone DE, Lowery P, Ambinder RF, Borrello IM, Swinnen LJ, Wagner-Johnston N, Gocke CB, Ali SA, Bolaños-Meade FJ, Varadhan R, Jones RJ. “Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70.” Blood Adv. 2019 Sep 10;3(17):2608-2616
Borrello I, Imus PH. “BCMA CAR T cells: the winding path to success.” J Clin Invest. 2019 Apr 29;129(6):2175-2177
Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P, Fuchs EJ, Levis M, Ambinder RF, Jones RJ, Gladstone DE. “Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.” Blood Adv. 2018 Sep 11;2(17):2226-2229. doi: 10.1182/bloodadvances.2018019208